Bristol Myers Squibb jumps after Q1 results and reaffirmed 2026 outlook

Bristol Myers Squibb (BMY) is up 5.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The move higher appears tied to Bristol Myers Squibb’s first-quarter results and management reaffirming full-year 2026 guidance while indicating performance is trending toward the upper end of its ranges. Investors also seemed to focus on continued momentum in the company’s Growth Portfolio, which helped offset expected declines in parts of the Legacy Portfolio.

Details:

Bristol Myers Squibb reported first-quarter 2026 revenue of $11.5 billion, up 3% year over year (about 1% excluding foreign exchange).

Growth Portfolio revenue rose 12% to $6.2 billion, with the company highlighting contributions from brands including Camzyos, Breyanzi, and Reblozyl.

The company reported GAAP EPS of $1.31 and non-GAAP EPS of $1.58 for the quarter.

Bristol Myers Squibb reaffirmed its 2026 guidance (revenue of about $46.0 billion to $47.5 billion and non-GAAP EPS of $6.05 to $6.35), and noted both metrics were trending toward the upper end of the ranges.

Sources:

Bristol Myers Squibb, Associated Press

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BMY Insider Trading Activity

$BMY insiders have traded $BMY stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BMY stock by insiders over the last 6 months:

DAVID V ELKINS (EVP, Chief Financial Officer) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $1,850,016.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

$BMY Hedge Fund Activity

We have seen 1,163 institutional investors add shares of $BMY stock to their portfolio, and 1,123 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 65,718,198 shares (-75.4%) from their portfolio in Q4 2025, for an estimated $3,544,839,600
AQR CAPITAL MANAGEMENT LLC added 16,332,924 shares (+172.6%) to their portfolio in Q4 2025, for an estimated $880,997,920
CAPITAL INTERNATIONAL INVESTORS removed 11,395,497 shares (-35.2%) from their portfolio in Q4 2025, for an estimated $614,673,108
JPMORGAN CHASE & CO removed 10,813,011 shares (-12.5%) from their portfolio in Q4 2025, for an estimated $583,253,813
WELLINGTON MANAGEMENT GROUP LLP removed 10,234,541 shares (-59.7%) from their portfolio in Q4 2025, for an estimated $552,051,141
MARSHALL WACE, LLP added 9,310,682 shares (+607.1%) to their portfolio in Q4 2025, for an estimated $502,218,187
PACER ADVISORS, INC. removed 9,304,698 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $501,895,410

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$BMY Government Contracts

We have seen $8,921,817 of award payments to $BMY over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

REVLIMID, POMALYST, CAMZYOS SPECIALTY PHARMACEUTICALS: $848,445
EMERGENCY BREYANZI INFUSION: $670,085

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$BMY Congressional Stock Trading

Members of Congress have traded $BMY stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BMY stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 12/19, 11/12 and 0 sales.
REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.

$BMY Analyst Ratings

Wall Street analysts have issued reports on $BMY in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Piper Sandler issued a "Overweight" rating on 02/23/2026
B of A Securities issued a "Buy" rating on 12/15/2025
Guggenheim issued a "Buy" rating on 12/12/2025

To track analyst ratings and price targets for $BMY, check out Quiver Quantitative's $BMY forecast page.

$BMY Price Targets

Multiple analysts have issued price targets for $BMY recently. We have seen 15 analysts offer price targets for $BMY in the last 6 months, with a median target of $60.0.

Here are some recent targets:

Tim Anderson from B of A Securities set a target price of $67.0 on 04/09/2026
Seamus Fernandez from Guggenheim set a target price of $72.0 on 04/08/2026
Carter Gould from Cantor Fitzgerald set a target price of $54.0 on 04/08/2026
Rajesh Kumar from HSBC set a target price of $60.0 on 03/17/2026
Trung Huynh from RBC Capital set a target price of $60.0 on 02/25/2026
David Amsellem from Piper Sandler set a target price of $75.0 on 02/23/2026
Emily Field from Barclays set a target price of $75.0 on 02/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.